WebApr 13, 2024 · Cambridge, UK, 13 April 2024 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, Inc (“Sierra”), the licence holder for SRA737 (a novel Chk1 inhibitor), has agreed to be acquired by GlaxoSmithKline plc (“GSK”) for US$1.9 billion in cash. The transaction is expected to close in the ... WebApr 13, 2024 · GSK Offers $1.9B for Cancer-Focused Pharma Co. Shares of Sierra Oncology Inc. traded 38% higher after the company reported it agreed to be acquired by GlaxoSmithKline Plc. for $55 per share in cash. Prior to the open of U.S. markets today, late-stage drug development company Sierra Oncology (SRRA:NASDAQ), which is engaged in …
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company …
WebApr 13, 2024 · By Natalie Grover and Yadarisa Shabong. (Reuters) - Britain's GlaxoSmithKline sought to bolster its cancer business on Wednesday by agreeing a $1.9 billion deal to buy … WebJan 25, 2024 · Late-stage data released Tuesday provide the most supportive evidence yet for their bet. They show that 25% of the patients given Sierra's drug, versus 9% in the active control group, reported at least a 50% reduction on a scorecard used to evaluate the severity of myelofibrosis symptoms. That result was enough for Sierra to claim success. buy rock band cheap
GSK Agrees To Acquire Sierra Oncology For $1.9 Bln Nasdaq
WebGSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth largest pharmaceutical company and #294 on the 2024 Fortune Global 500, ranked behind other … WebApr 13, 2024 · (RTTNews) - GlaxoSmithKline plc (GSK, GSK.L), on Wednesday, announced an agreement to acquire late-stage biopharmaceutical company Sierra Oncology Inc. (SRRA) for $55 per share of common stock in ... WebApr 19, 2024 · The Sierra Oncology acquisition looks to be smart business based on paying $1.9bn for a company close to bringing a drug with ~$1.7bn peak sales expectations to market, and there is cash available ... ceramic vases with handles